Alderson, D., Cunningham, D., Nankivell, M., Blazeby, J. M., Griffin, S. M., Crellin, A., . . . Langley, R. E. (2017). Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): An open-label, randomised phase 3 trial. Lancet Oncol.
Chicago-stil citatAlderson, Derek, et al. "Neoadjuvant Cisplatin and Fluorouracil Versus Epirubicin, Cisplatin, and Capecitabine Followed By Resection in Patients With Oesophageal Adenocarcinoma (UK MRC OE05): An Open-label, Randomised Phase 3 Trial." Lancet Oncol 2017.
MLA-referensAlderson, Derek, et al. "Neoadjuvant Cisplatin and Fluorouracil Versus Epirubicin, Cisplatin, and Capecitabine Followed By Resection in Patients With Oesophageal Adenocarcinoma (UK MRC OE05): An Open-label, Randomised Phase 3 Trial." Lancet Oncol 2017.